137 related articles for article (PubMed ID: 38804898)
61. Strategies for Assessing Acceptable Intakes for Novel
Ponting DJ; Dobo KL; Kenyon MO; Kalgutkar AS
J Med Chem; 2022 Dec; 65(23):15584-15607. PubMed ID: 36441966
[TBL] [Abstract][Full Text] [Related]
62. Nitrosamines crisis in pharmaceuticals - Insights on toxicological implications, root causes and risk assessment: A systematic review.
Vikram HPR; Kumar TP; Kumar G; Beeraka NM; Deka R; Suhail SM; Jat S; Bannimath N; Padmanabhan G; Chandan RS; Kumar P; Gurupadayya B
J Pharm Anal; 2024 May; 14(5):100919. PubMed ID: 38799236
[TBL] [Abstract][Full Text] [Related]
63. Regulatory Experiences with Root Causes and Risk Factors for Nitrosamine Impurities in Pharmaceuticals.
Horne S; Vera MD; Nagavelli LR; Sayeed VA; Heckman L; Johnson D; Berger D; Yip YY; Krahn CL; Sizukusa LO; Rocha NFM; Bream RN; Ludwig J; Keire DA; Condran G
J Pharm Sci; 2023 May; 112(5):1166-1182. PubMed ID: 36599405
[TBL] [Abstract][Full Text] [Related]
64. Use of the benchmark-dose (BMD) approach to derive occupational exposure limits (OELs) for genotoxic carcinogens: N-nitrosamines.
Blum K; FitzGerald R; Wilks MF; Barle EL; Hopf NB
J Appl Toxicol; 2023 Aug; 43(8):1183-1200. PubMed ID: 36840679
[TBL] [Abstract][Full Text] [Related]
65. The EU Response to the Presence of Nitrosamine Impurities in Medicines.
Ruepp R; Frötschl R; Bream R; Filancia M; Girard T; Spinei A; Weise M; Whomsley R
Front Med (Lausanne); 2021; 8():782536. PubMed ID: 34869504
[TBL] [Abstract][Full Text] [Related]
66. Impact of agricultural activities on the occurrence of
Chen Y; Huang H; Chen W; Huang X; Zhang Y; Liang Y; Zeng H; Zhang H; Qi S
Environ Sci Process Impacts; 2024 Mar; 26(3):470-482. PubMed ID: 38282562
[No Abstract] [Full Text] [Related]
67. Presence of nitrosamine impurities in medicinal products.
Sedlo I; Kolonić T; Tomić S
Arh Hig Rada Toksikol; 2021 Mar; 72(1):1-5. PubMed ID: 33787187
[TBL] [Abstract][Full Text] [Related]
68. Role of Carbonyl Compounds for
Pan Y; Breider F; Barrios B; Minakata D; Deng H; von Gunten U
Environ Sci Technol; 2024 Mar; 58(10):4792-4801. PubMed ID: 38427382
[No Abstract] [Full Text] [Related]
69. A GC-MS/MS Method for Trace Level Quantification of Six Nitrosamine Impurities (NDMA, NDEA, NEIPA, NDIPA, NDPA, and NDBA) in Commercially Used Organic Solvents: Dichloromethane, Ethyl Acetate, Toluene, and O-xylene.
Kosuri ER; Bhanti M; Jaywant MA; Han M; Wang X; Obeng M
J Pharm Sci; 2023 May; 112(5):1225-1230. PubMed ID: 36462706
[TBL] [Abstract][Full Text] [Related]
70. Quantum-Mechanical Approach to Predicting the Carcinogenic Potency of
Kostal J; Voutchkova-Kostal A
Chem Res Toxicol; 2023 Feb; 36(2):291-304. PubMed ID: 36745540
[No Abstract] [Full Text] [Related]
71. Mechanistic Insight into the Degradation of Nitrosamines via Aqueous-Phase UV Photolysis or a UV-Based Advanced Oxidation Process: Quantum Mechanical Calculations.
Minakata D; Coscarelli E
Molecules; 2018 Feb; 23(3):. PubMed ID: 29495565
[TBL] [Abstract][Full Text] [Related]
72. Endogenous formation of nitrosamines and oxidative DNA-damaging agents in tobacco users.
Nair J; Ohshima H; Nair UJ; Bartsch H
Crit Rev Toxicol; 1996; 26(2):149-61. PubMed ID: 8688158
[TBL] [Abstract][Full Text] [Related]
73. Intake of volatile nitrosamines by Chinese residents in different provinces via food and drinking water.
Li X; Bei E; Qiu Y; Xiao H; Wang J; Lin P; Zhang X; Chen C
Sci Total Environ; 2021 Feb; 754():142121. PubMed ID: 32911156
[TBL] [Abstract][Full Text] [Related]
74. Hazard assessment of nitrosamine and nitramine by-products of amine-based CCS: alternative approaches.
Buist HE; Devito S; Goldbohm RA; Stierum RH; Venhorst J; Kroese ED
Regul Toxicol Pharmacol; 2015 Apr; 71(3):601-23. PubMed ID: 25604881
[TBL] [Abstract][Full Text] [Related]
75. Theoretical study of N-nitrosamines and their presumed proximate carcinogens.
Andreozzi P; Klopman G; Hopfinger AJ
Cancer Biochem Biophys; 1980; 4(4):209-20. PubMed ID: 7448745
[TBL] [Abstract][Full Text] [Related]
76. Metabolic Activation and Carcinogenesis of Tobacco-Specific Nitrosamine N'-Nitrosonornicotine (NNN): A Density Function Theory and Molecular Docking Study.
Fan T; Sun G; Zhao L; Cui X; Zhong R
Int J Environ Res Public Health; 2019 Jan; 16(2):. PubMed ID: 30634532
[TBL] [Abstract][Full Text] [Related]
77. A Multi-Analyte LC-MS/MS Method for Determination and Quantification of Six Nitrosamine Impurities in Sartans like Azilsartan, Valsartan, Telmisartan, Olmesartan, Losartan and Irbesartan.
Gopireddy RR; Maruthapillai A; Mahapatra S
J Chromatogr Sci; 2024 Feb; 62(2):147-167. PubMed ID: 35830866
[TBL] [Abstract][Full Text] [Related]
78. Prevalence of nitrosamine contaminants in drug samples: Has the crisis been overcome?
Schmidtsdorff S; Neumann J; Schmidt AH; Parr MK
Arch Pharm (Weinheim); 2023 Feb; 356(2):e2200484. PubMed ID: 36461687
[TBL] [Abstract][Full Text] [Related]
79. Investigation of Carcinogenic Impurities of N-Nitrosamines in Sartan Pharmaceutical Products Marketed in Brazil: Development and Validation of Method Based on High-Performance Liquid Chromatography-Tandem Mass Spectrometry.
Monteiro MA; de Lima PC; Novotny TS; Santana DS; Lima MED; Dantas ASCL; Ferreira LODS; de Souza MN; Maranho RLDN; Ochs SM
J Pharm Sci; 2023 May; 112(5):1305-1314. PubMed ID: 36657719
[TBL] [Abstract][Full Text] [Related]
80. Formation of formaldehyde adducts in the reactions of DNA and deoxyribonucleosides with alpha-acetates of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), and N-nitrosodimethylamine (NDMA).
Cheng G; Wang M; Upadhyaya P; Villalta PW; Hecht SS
Chem Res Toxicol; 2008 Mar; 21(3):746-51. PubMed ID: 18205321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
